In light of emerging adverse trends in travel vaccine uptakes across our key markets, driven by geopolitical factors, we adjust our product sales guidance to 135 to 150 million euros for the fiscal year 2026, and total revenues to 145 to 160 million euros.

May 13, 2026 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2026-05-13 | transcript 9c98ecfd-5409-4f3c-9670-b292471c4998 | chars 14122-14378 | segment 14

The chiaro sales reached 27.5 million euros, 65.5% above last year, and the year-over-year growth is driven by a strong increase in sales to US military, but also into the travel channels.

May 7, 2025 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2025-05-07 | transcript 308d872c-9ed4-4d37-a8a8-a6fc443ed75b | chars 11705-11893 | segment 11

Ixiaro sales into the travel market also delivered growth over the first half year, despite supply constraints experienced during the first quarter.

Aug 13, 2024 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2024-08-13 | transcript 92752cd0-9a10-4822-93fe-d645ec35ec4b | chars 17299-17447 | segment 17

The increase in Ducoral sales is primarily driven by the continued recovery in the private travel market.

May 7, 2024 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2024-05-07 | transcript c4d4b639-473c-4a9a-bf8b-6fd765eebe14 | chars 11849-11954 | segment 12

The very positive sales performance continues to be, as already mentioned, related to the recovery of global travel markets, several of which have reached or even exceeded pre-COVID levels, and we expect this trend to continue.

Mar 20, 2024 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2024-03-20 | transcript d9d99c70-eeb3-4bb3-ab00-b218bd637c55 | chars 14240-14467 | segment 14

Product sales reached 69.7 million euros and grew 109% over prior year. At constant currency, product sales grew 113.6%. The strong growth is driven by all product lines, with Ixiara growing at 150% at constant currency, Ducoral at 213% and third-party product at 46.8%. This excellent sales performance is primarily driven by the recovery of the private travel market, but also by price increases across the board.

Sep 21, 2023 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2023-09-21 | transcript 9016c879-b696-4e87-8cfa-6ea940791d29 | chars 15467-15882 | segment 15

The decrease in sales to U.S. military was partially offset by significant increase of sales in the travel market, of 300%.

Mar 23, 2023 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2023-03-23 | transcript 89aa2a9d-4fa2-4edd-8dda-f5caa3c3555f | chars 9409-9532 | segment 9

DoCoral sales reached 17.3 million euros compared to 2.4 million euros in 2022, an increase of more than 600%, once again driven by the recovery of the travel market.

Mar 23, 2023 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2023-03-23 | transcript 89aa2a9d-4fa2-4edd-8dda-f5caa3c3555f | chars 9533-9699 | segment 9

The very positive sales performance in our travel vaccine is, as already mentioned, related to a travel market recovering faster than expected.

Mar 23, 2023 / CFO / receipt, needs a key / Peter Buehler, CFO | earnings call 2023-03-23 | transcript 89aa2a9d-4fa2-4edd-8dda-f5caa3c3555f | chars 9960-10103 | segment 9